Viridian Therapeutics, Inc. (VRDN)
30.87
+0.39
(+1.28%)
USD |
NASDAQ |
Nov 13, 16:00
31.02
+0.15
(+0.49%)
After-Hours: 07:56
Viridian Therapeutics EPS Diluted (Quarterly) : -0.8924 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.8924 |
| June 30, 2026 | -1.178 |
| March 31, 2026 | -1.026 |
| December 31, 2025 | -1.080 |
| September 30, 2025 | -0.423 |
| June 30, 2025 | -1.235 |
| March 31, 2025 | -1.068 |
| December 31, 2024 | -0.8076 |
| September 30, 2024 | -1.155 |
| June 30, 2024 | -1.018 |
| March 31, 2024 | -0.7945 |
| December 31, 2023 | -1.346 |
| September 30, 2023 | -1.092 |
| June 30, 2023 | -1.273 |
| March 31, 2023 | -1.613 |
| December 31, 2022 | -1.129 |
| September 30, 2022 | -0.8566 |
| June 30, 2022 | -1.062 |
| March 31, 2022 | -0.9834 |
| December 31, 2021 | -1.309 |
| September 30, 2021 | -1.256 |
| June 30, 2021 | -2.216 |
| March 31, 2021 | -2.913 |
| December 31, 2020 | -23.07 |
| September 30, 2020 | -1.477 |
| Date | Value |
|---|---|
| June 30, 2020 | -1.819 |
| March 31, 2020 | -2.653 |
| December 31, 2019 | -4.687 |
| September 30, 2019 | -5.420 |
| June 30, 2019 | -4.307 |
| March 31, 2019 | -5.648 |
| December 31, 2018 | -5.018 |
| September 30, 2018 | -4.399 |
| June 30, 2018 | -4.35 |
| March 31, 2018 | -2.70 |
| December 31, 2017 | -4.35 |
| September 30, 2017 | -4.05 |
| June 30, 2017 | -5.10 |
| March 31, 2017 | -9.00 |
| December 31, 2016 | -107.69 |
| September 30, 2016 | -1557.00 |
| June 30, 2016 | -51.75 |
| March 31, 2016 | -58.50 |
| December 31, 2015 | -63.04 |
| September 30, 2015 | -87.75 |
| June 30, 2015 | -74.25 |
| March 31, 2015 | -101.25 |
| December 31, 2014 | -134.32 |
| September 30, 2014 | -96.75 |
| June 30, 2014 | -254.25 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Travere Therapeutics, Inc. | -0.645 |
| Arrowhead Pharmaceuticals, Inc. | -3.029 |
| Vertex Pharmaceuticals, Inc. | 2.561 |
| TG Therapeutics, Inc. | 0.3557 |
| ACADIA Pharmaceuticals, Inc. | 0.305 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -101.21M |
| Revenue (Quarterly) | 25.75M |
| Total Expenses (Quarterly) | 126.96M |
| Enterprise Value | 2.889B |
| Gross Profit Margin (Quarterly) | 92.74% |
| Profit Margin (Quarterly) | -393.0% |
| Earnings Yield | -13.53% |
| Normalized Earnings Yield | -13.70 |